Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Icon's gross business awards demonstrated an 11% increase on a sequential basis, driven by significant wins from biotech clients and the strengthening of partnerships with large pharmaceutical companies. The company has successfully met or exceeded its financial targets related to the PRA acquisition, positioning itself favorably against funding environment uncertainties while allowing for potential acceleration in clinical trial research. Furthermore, Icon's improving win rate within its client segment underscores its advantageous business mix and enhanced access to key industry players, contributing to a positive long-term outlook.

Bears say

The report indicates that Icon's EBITDA margin expectations for 2025 have been revised downward to the high-19% range, compared to earlier expectations of approximately 20%. This decrease is primarily attributed to unfavorable dynamics affecting gross margins, even though revenue guidance has been raised and EPS margins remain unchanged. Additionally, there are significant downside risks due to factors such as slowed clinical trial activities, uncertainty in biotech funding, and potential impacts from inflation and a slowdown in pharmaceutical R&D spending.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.